Last reviewed · How we verify
Use of insulin glargine twice daily — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Use of insulin glargine twice daily (Use of insulin glargine twice daily) — Eastern Virginia Medical School.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Use of insulin glargine twice daily TARGET | Use of insulin glargine twice daily | Eastern Virginia Medical School | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Use of insulin glargine twice daily CI watch — RSS
- Use of insulin glargine twice daily CI watch — Atom
- Use of insulin glargine twice daily CI watch — JSON
- Use of insulin glargine twice daily alone — RSS
Cite this brief
Drug Landscape (2026). Use of insulin glargine twice daily — Competitive Intelligence Brief. https://druglandscape.com/ci/use-of-insulin-glargine-twice-daily. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab